DexCom/$DXCM
DexCom shares rise after a Q3 earnings beat, higher FY26 revenue guidance and a new $1bn share-repurchase authorisation.
5 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About DexCom
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
- Ticker
- $DXCM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 11,050
- Headquarters
- San Diego, United States
- Website
- www.dexcom.com
DexCom Metrics
BasicAdvanced
$30B
31.51
$2.54
1.42
-
Price and volume
Market cap
$30B
Beta
1.42
52-week high
$92.59
52-week low
$54.11
Average daily volume
4.5M
Financial strength
Current ratio
1.733
Quick ratio
1.37
Long term debt to equity
0.526
Total debt to equity
0.514
Interest coverage (TTM)
75.94%
Profitability
EBITDA (TTM)
1,403.2
Gross margin (TTM)
62.47%
Net profit margin (TTM)
20.12%
Operating margin (TTM)
22.92%
Effective tax rate (TTM)
21.90%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
10.33%
Return on equity (TTM)
38.49%
Valuation
Price to earnings (TTM)
31.514
Price to revenue (TTM)
6.213
Price to book
11.51
Price to tangible book (TTM)
12.09
Price to free cash flow (TTM)
21.974
Free cash flow yield (TTM)
4.55%
Free cash flow per share (TTM)
3.638
Growth
Revenue change (TTM)
15.54%
Earnings per share change (TTM)
77.35%
3-year revenue growth (CAGR)
15.83%
10-year revenue growth (CAGR)
26.08%
3-year earnings per share growth (CAGR)
43.16%
10-year earnings per share growth (CAGR)
26.25%
What the Analysts think about DexCom
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
Analyst projections of the future price of DexCom stock.
Bulls say / Bears say
Third-quarter revenue rose 11%, with US sales up 14%, and Dexcom lifted its 2026 revenue and operating-margin outlook. This points to continued growth alongside improving profitability. (Dexcom)
Dexcom expects its 15-day G7 system to reach nearly half of its US customer base by year-end, helped by broad pump connectivity. Longer wear and improving sensor survivability could support retention and product uptake. (Stock Analysis)
In the CONNECT trial, G7 users with type 2 diabetes not using insulin achieved a 1.6 percentage-point average A1C reduction, 0.9 points more than routine care. This evidence could help support broader CGM use and reimbursement in a wider patient group. (Dexcom, MedTech Dive)
International revenue grew just 5% in the third quarter, versus 14% in the US, as Dexcom lapped earlier reimbursement wins. That leaves overseas growth less robust for now. (Stock Analysis)
CGM demand is drawing stronger competition from established rivals including Abbott and Medtronic. More intense rivalry could make it harder for Dexcom to defend share and pricing. (Reuters)
The new Ireland facility is still ramping up, and management expects the start-up phase to weigh on margins in the near term. If the ramp takes longer than planned, it could delay margin progress. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
DexCom Financial Performance
Revenues and expenses
DexCom Earnings Performance
Company profitability
Upcoming events
No upcoming events
DexCom News
AllArticlesVideos
Funds containing DexCom
AllUSDEURGBP
Fund name | Fund size | $DXCM weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 1.16% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.16% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.16% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.60% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 0.60% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.